The Effects of Levodopa on Albinism
Abstract
Albinism, a refractory disease with reduced pigmentation. And it has caused great distress to the patient's body and mind. How to treat the disease is a troubling problem in history. Levodopa, a medicine is used when needed to treat the return of Parkinson’s symptoms. However, since the last century, some doctors have proposed using levodopa to treat albinism. The results of the experiment were not very significant. We research the effects of levodopa on albinism from mechanism of action, clinical trial, molecular mechanism and clinical studies. We find that levodopa has only a weak or no effect on fetuses with albinism.
References
Liu Siyin,Kuht Helen J.,Moon Emily Haejoon,Maconachie Gail DE.,Thomas Mervyn G.. Current and Emerging Treatments for Albinism[J]. Survey of Ophthalmology,2020 (prepublish).
C Gail Summers MD,John E Connett PhD,Ann M Holleschau BA,Jennifer L Anderson BS,Inge De Becker MD,Brian S McKay PhD,Murray H Brilliant PhD. Does levodopa improve vision in albinism? Results of a randomized, controlled clinical trial[J]. Clinical & Experimental Ophthalmology,2014,42(8).
Helena Lee,Jennifer Scott,Helen Griffiths,Jay E. Self,Andrew Lotery. Oral levodopa rescues retinal morphology and visual function in a murine model of human albinism[J]. Pigment Cell & Melanoma Research,2019,32(5).
Lopez VM, Decatur CL, Stamer WD, Lynch RM, McKay BS. L-DOPA is an endogenous ligand for OA1. PLoS Biol. 2008; 6: e236.
Espay AJ. Commentary for "Chediak-Higashi syndrome presenting as young-onset levodopa-responsive parkinsonism". Mov Disord. 2013 Feb;28(2):129-30. doi: 10.1002 /mds.25392. PMID: 23436632.
Ilia M, Jeffery G. Retinal cell addition and rod production depend on early stages of ocular melanin synthesis. J Comp Neurol. 2000; 420: 437–444.
Elisabetta De Filippo, Prashiela Manga, Anke C. Schiedel; Identification of Novel G Protein–Coupled Receptor 143 Ligands as Pharmacologic Tools for Investigating X-Linked Ocular Albinism. Invest. Ophthalmol. Vis. Sci. 2017;58(7):3118-3126. doi: https://doi.org/10.1167/iovs.16-21128.
Self J , Lee H . Novel therapeutics in nystagmus- what has the genetics taught us so far?[J]. 2021.
Copyright (c) 2023 Yi Hao, Huina Ma, Siyuan Wang, Hairu Yan, Wei Zhou
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors contributing to this journal agree to publish their articles under the Creative Commons Attribution-Noncommercial 4.0 International License, allowing third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, that the work is not used for commercial purposes, and that in the event of reuse or distribution, the terms of this license are made clear. With this license, the authors hold the copyright without restrictions and are allowed to retain publishing rights without restrictions as long as this journal is the original publisher of the articles.
